Silver Book Fact
After 54 weeks of receiving bevacizumab, wet age-realted macular degeneration (AMD) patients were more likely to gain at least 6 letters of contrast sensitivity than patikents recieving standard care–35.4% versus 15.2%.
Patel J, Chen F, Da Cruz L, Rubin G, et al. Contrast Sensitivity Outcomes in the ABC Trial: A randomized trial of bevacizumab for neovascular age-related macular degeneration. Invest Ophthalmol Vis Sci. February 2011; 52(6): 3089-93. http://www.iovs.org/content/early/2011/02/09/iovs.10-6208.full.pdf